Non-small cell lung cancers (NSCLC) with excision repair cross-complementation group 1 (ERCC1) deficiency were exquisitely sensitive to NAMPT inhibitors, in vitro and in vivo (98). The gene discussed is NAMPT; the disease is non-small cell lung carcinoma.